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Ectopic (or tertiary) lymphoid structures (ELS) are organized aggregates of lymphocytes resem-
bling secondary lymphoid organs and developing in chronically inflamed nonlymphoid tissues dur-
ing persistent infections, graft rejection, autoimmune conditions, and cancer. In this review, we
will first depict the mechanisms regulating ELS generation, focusing on the role played by lym-
phoid chemokines. We will then characterize ELS forming in target organs during autoimmune
conditions, here exemplified by rheumatoid arthritis, and cancer, highlighting the relevance of the
tissue-specific factors. Finally, we will discuss the clinical significance of ELS and the therapeutic
potential of their inhibition and/or enhancement depending on the disease considered.
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1 INTRODUCTION
Chemokines are small (7–12 kDa) chemotactic polypeptides sharing
a common structural motif1 and able to direct lymphocyte recruit-
ment and organize the architecture of lymphoid organs in health
and disease.2 Chemokines’ structure is characterized by four con-
served cysteine residues (C). When the first two CC are sequen-
tial, chemokines are defined CCL; conversely, if the CC sequence is
divided by a single amino acid (X), they are labeled CXCL.3 More
recently, another unique subfamily of chemokines has been discov-
ered and named CX3C. This includes only one member (fractalkine or
CX3CL1), which, atypically, can exist in either a membrane-bound or a
soluble form.4
Chemokines are produced by multiple cell subsets and can be
categorized according to the nature of the expressing cells. Home-
ostatic chemokines, for example, CXCL12, CXCL13, CCL19, and
CCL21 are constitutively expressed in lymphoid organs; inflammatory
chemokines such as CXCL1, CXCL2, andCXCL3 are typically produced
in response to inflammation.5
Both lymphocyte migration and segregation of B and T cells in
their characteristic microcompartments in lymphoid organs depend
on the interaction between chemokines and their G-protein coupled
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receptors,2 for example, CXCL12 binding CXCR4, CXCL13 binding
CXCR5, CCL19 and CCL21 binding CCR7.2
Lymphoid organs are highly differentiated compartments responsi-
ble for coordinating and guiding the differentiation and proliferation of
lymphocytes, hence directing immunologic responses in all their com-
plexity. Bonemarrow and thymus, defined as primary lymphoid organs,
are the anatomic sites dedicated to the selection and maturation of
naïve B and T lymphocytes from immature hematopoietic precursors.
Secondary lymphoid organs (SLOs) coordinate adaptive immunologic
responses through the trafficking of lymphocytes fromperipheral sites
following antigen (Ag) encounter6 via afferent lymphatics andmaintain
immune tolerance to auto-Ag.7 SLOs include spleen, lymph nodes, and
mucosal-associated lymphoid tissue (MALT) such as Peyer’s patches
and tonsil.
Chronically inflamed nonlymphoid tissues can also host highly
organized aggregates of lymphocytes known as tertiary lymphoid
organs (TLOs) or ectopic lymphoid structures (ELS). These structures
usually occur in the course of persistent infections, transplant rejec-
tion, cancer (reviewed in Ref. 8), and autoimmune diseases (reviewed
in Ref. 9), in response to mediators of inflammation like chemokines,
cytokines, and bioactive lipids produced by tissue-resident cells and
able to regulate the recruitment and organization of lymphocytes. In
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some circumstances, ELS acquire the name related to the anatomic
district in which they develop, for instance, iBALT (inducible bronchus-
associated lymphoid tissue) in the lungs.10 The process responsible for
the development of ELS is called ectopic lymphoid neogenesis (ELN)
and, differently from primary and secondary lymphoid organogenesis,
it occurs after birth and is not genetically programmed.11
ELS are dynamic structures resembling the cellular arrangement of
SLO. Although with varying degrees of organization, ELS are typically
characterized by (i) a distinct T-lymphocytes rich zone enclosing
a central B-cell rich area; (ii) a network of follicular dendritic cells
(FDCs) and activated stromal mesenchymal cells (e.g., lymphoid tissue
fibroblasts)12,13; (iii) plasmablasts and plasma cells surrounding the
T cell rich area; and (iv) high endothelial venules (HEVs), which are
postcapillary blood vessels normally not found in peripheral tissue
but typical of SLOs and dedicated to favoring the migration of naïve
lymphocytes into SLOs.
ELS share the genetic profile of SLOs, including the expression
of genes encoding lymphoid chemokines and lymphotoxins (LTs),
and often contain functionally active germinal centers (GCs) able
to mediate in situ B cell differentiation, somatic hypermutation,
oligoclonal expansion and, eventually, antibodies production. The
critical factors driving ectopic neogenesis of lymphoid structures in
peripheral diseased tissues, including lymphoid chemokines, overlap
substantially with the molecular machinery supporting SLOs’ prenatal
development.14 Nevertheless, the cellular components producing
these key modulators may differ in ELS. A few architectural dissimilar-
ities between ELS and SLOs also exist: while the SLOs are enclosed by
a fibrous capsule and have an independent afferent lymphatic vessel
(except forMALT), ELS lackboth, formdeeplywithin the connective tis-
sue and are exposed directly to Ag and regulatorymolecules produced
within the inflamed tissue.15 Such microarchitectural differences of
ELS, in the case of persistent infections, could improve the immuno-
logic response, enhancing the production of antibodies directed
against the pathogenic microorganisms. Similarly, several findings also
support a beneficial role for ELS in cancer. Conversely, in tissues target
of autoimmune processes, the constitutive exposure to the auto-Ag
not only can favor the development of ELS but also, in turn, expand the
autoreactive response with the proliferation of autoreactive T and B
cells and increase the local production of autoantibodies.16
Here, we will initially describe the regulatory mechanisms of the
ELS generation, using SLOs as a comparator and focusing on the role
played by lymphoid chemokines. We will then define peculiar fea-
tures acquired by ELS when forming in target organs in the course
of certain pathologic conditions, specifically rheumatoid arthritis (RA)
and cancer.
2 REGULATORY MECHANISMS
OF THE ELN: THE KEY ROLE
OF HOMEOSTATIC CHEMOKINES
The development of both SLOs and ELS is a rather sophisticated and
finely regulatedmechanism, which is largely orchestrated by lymphoid
chemokines, cytokines, adhesionmolecules, and survival factors.17
During the embryonic life, the early phase of the sec-
ondary lymphoid organogenesis involves the crosstalk between
the hematopoietic-derived CD3−CD4+IL-7Ra+RANK+ and/or
CD3−CD4−CD45+IL-7Ra−RANK+CD11c+CD11b+ lymphoid tis-
sue inducer/initiators (LTi) cells and the mesenchymal lymphoid
tissue organizer (LTo) VCAM-1+ICAM-1+LT𝛽R+ cells.11,18 The inter-
action between LT 𝛼1𝛽2 (LT𝛽), produced by LTi, and its receptor
LT𝛽R, expressed by LTo cells, initiates the secondary events of the
SLOs generation.15 These take place in the presence of IL-7 and
RANK-ligand and consist of the recruitment and the retention of
lymphocytes. The former is determined by the high gradient of
CXCL13, CCL19, and CCL21 produced by LTo cells in response to
LT𝛽 , whereas the latter occurs through the up-regulation of the
adhesion molecules (VCAM1, ICAM1) and peripheral nodal addressin
(PNAd) in HEVs and stromal cells.11,19 The expression of CXCR5
and CCR7 on the surface of LTi confers to these cells the ability to
respond to CXCL13 and CCL19/CCL21, respectively. Eventually,
LT𝛽/LT𝛽-R, CXCL13/CXCR5,11 and CCL19/CCL21/CCR720 sustain
the recruitment and segregation of B/T cells in distinct areas.21
The chief role of the CXCL13/CXCR5 during the lymphoid organo-
genesis has been demonstrated in animalmodels inwhich this axis was
either silenced or overexpressed. Mice deficient for CXCL13/CXCR5
showed an incomplete maturation of the lymph nodes, with some
of them formed and some others missing.22 The overexpression of
this pathway prompted the LT𝛽-dependent development of ELS in
nonlymphoid organs.21
Along with the CXCL13/CXCR5 axis, also CCR7, the common
receptor for CCL19 and CCL21, plays a relevant role in the ini-
tial phase of the lymphoid organogenesis.20 Mice deficient for CCR7
have, at birth, almost all the SLOs as their wild-type counterparts,
though the lymphocytes segregation in these organs is impaired
and the architecture altered.23 Overall, the effect of CCR7 and
CXCR5 and their cognate ligands is synergic; in fact, in CCR7/CXCR5-
double knockout (KO) mice the number of undeveloped lymph
nodes is higher compared with the single KO for each of these
chemokine receptors.24
Conversely to SLOs, the primum movens of the ELS generation in
peripheral nonlymphoid adult tissues has not been entirely elucidated
yet. Specific inflammatory signals and the cellularmicroenvironmentof
the tissue are critical elements, as suggested by the preferential devel-
opment of theELS in particular tissue/organs (“permissive tissues”) and
in certain but not all patients.25 For example, the overexpression of the
homeostatic chemokineCCL21 in animalmodels is sufficient for induc-
ing ELN in the pancreas but not in the skin.26
Similarly to SLOs, the immune cells infiltrating the target tissue dur-
ing the inflammatory process behave as inducers of ELS27; on the other
hand, the resident stromal cells mirror the activity of the mesenchy-
mal LTo as seen during the secondary lymphoid organogenesis.12,28,29
Stromal cells include fibroblasts, endothelial and epithelial cells,
and pericytes.30
As it happens in SLOs, homeostatic lymphoid chemokines are essen-
tial for the correct clustering of B/T cells and the development of
adequately arranged lymphoid structures.14,31 Nevertheless, in non-
lymphoid organs, the ectopic generation of lymphoid follicles may
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require additional signals provided by the chronically inflamed tissue,
for example, persistent Ag presentation.17
With regards to the infiltrating immune cells acting as inducers,
the development of ELS has been shown to be strongly dependent
on the presence of the Th17 subset of cells and its eponymous
cytokine IL-17 in animal models of lung inflammation, multiple
sclerosis, and inflammatory arthritis.32,33 Specifically, the expres-
sion of the glycoprotein podoplanin seems to be critical.27 The
migration and retention of Th17 cells is likely related related to the
CCL20/CCR6 axis. In fact, Th17, alongside with immature dendritic
cells (DCs), express CCR6,17 which represents the cognate receptor
of the chemokine CCL20. Studies characterizing tertiary lymphoid
structures forming in lungs during idiopathic/heritable pulmonary
arterial hypertension demonstrated high levels of CCL20 within the
ELS, and a substantial infiltration of CCR6+IL17+ T cells CCL20-
sustained.34 IL-17, however, is not the only cytokine involved: in
fact, also IL-23 and IL-22, respectively upstream and downstream
of the Th17 signaling, promote ELN in target organs, as observed
in rheumatoid synovial tissue35 and salivary glands in experimental
Sjogren’s syndrome.36
It has been recently described that a group of innate lymphoid
cells (ILC), probably ancestrally linked to the Th17 cells, and called
“adult LTi”37,38 can also contribute to the development of ectopic lym-
phoid tissue. This process occurs by exploiting the same downstream
pathway used by the Th17 subset.33,39 Furthermore, it has lately
emerged that also IL-21-producing and ICOS-expressing T follicular
helper (Tfh) cells may be involved in ELS generation and activities,
as the organization of the GC and the production of high-affinity
immunoglobulins appear deranged in the absence of Tfh.40 In line
with that, an increased rate of circulating Tfh cells can be detected
in several autoimmune conditions characterised by ELS formation.41
Notably, some features typical of Tfh, for example, IL-21 and ICOS
production/expression, can also be acquired by Th17 cells during
their differentiation.8,42–44
If Th17 cells, adult LTi-Th17-like cells and Tfh cells are contribu-
tors to ELS, a growing body of evidence has instead suggested that
immunosuppressive Foxp3+ T regulatory (Treg) cells may act as neg-
ative regulators of the ELN, in particular by preventing the develop-
ment of HEVs.45 T cell subsets are not the only immune cells able to
induce TLOs neogenesis; inflammatory macrophages (M1-polarized)
have been indeed described to be able to stimulate vascular smooth
muscle cells to express homeostatic chemokines which, eventually,
lead to ELS formation.46
Overall, the cytokines released by the immune cells acting as induc-
ers of ELS prompt the production of essential lymphoid chemokines
such as CXCL13 and CXCL12 which, in turn, promote the recruit-
ment of naïve B cells. The chemotactic gradient of CXCL13 consti-
tutes a potent homing signal for the CXCR5+ B lymphocytes. Once
recruited into the follicle, B cells further sustain ELS formation by
producing LT𝛽 . Tfh cells not only participate as potential inducers
of ELS but they underpin the biologic activity of B cells, including
the differentiation into antibodies producing cells within the GC.47
Tfh cells express CXCR5, which gives them the ability to respond to
CXCL13 and locate in the proximity of B cells in ELS, thus providing the
environment for Ag-specific B cells help. Remarkably, Tfh cells become
themselves producers of CXCL13 contributing to the formation of
second immunologic synapses.48,49
Though in TLOs the micro-anatomic organization in dark and light
zone is not as well defined as in SLOs, the functionality of local anti-
bodies production relies on the shuttling of B-lymphocytes between
the equivalent of the dark and light zone. GC B cells accumulate at
the site of the Ag selection in the light zone following CXCL13 chemo-
attraction, whereas centroblasts expressing CXCR4 are recruited in
the dark zone, site of somatic hypermutation, in response to CXCL12
predominantly releasedby the tingible bodymacrophages.28 CXCR5+-
Tfh cells, attracted by CXCL13, are recruited inside the follicle where
they can contribute to the establishment of the GC.50 Vice versa, high
levels of CCL19 andCCL21 keepCCR7+ un-primedT cells towards the
periphery, outside the follicle.
Although its role is yet to be fully defined, the unique chemokine
CX3CL1 seems to be likewise involved in the generation of
ELS in autoimmune diseases (i.e., in salivary glands of Sjo-
gren’s syndrome), possibly by attracting CX3CR1+-precursors of
resident DCs.51
A primary role in the lymphocytes recruitment and retention
in both SLOs and ELS is played by the HEVs. These are peculiar
vascular structures characteristic of lymphoid organs. During sec-
ondary lymphoid organogenesis, HEVs are generated in response to
factors released by LTo, for example, fibroblast growth factor-2.11
In nonlymphoid peripheral inflamed tissue, HEVs seem to become
PNAd-expressing upon the initial interaction between T and DC cells
surrounding the blood vessels.52
The diapedesis and the homing of naïve T cells to SLOs and TLOs
require the initial interaction between PNAd, expressed by the high
endothelial cells inHEVs, and its ligandL-selectin/CD62L, expressedby
lymphocytes.53,54 Subsequently, CCR7-expressingT cells are attracted
towards their cognate ligands CCL19/CCL21, which are produced on
the abluminal side of the HEVs in the T cell area.20
PNAd+ endothelial cells themselves are an additional source of
the CCR7-ligand CCL21 in order to be posted on the luminal surface
and initiate the adhesion cascade and the transmigration of CCR7+ L-
selectin+ Naïve T cells.52,55 Mature DCs, which are CCR7+ cells, sim-
ilarly migrate to the SLOs/TLOs following CCL19/CCL21 gradient. B
cells can express CCR7 on their surface too, yet they use it only dur-
ing the adhesion phase to the endothelium of HEVs since the trans-
migration to the follicle is primarily guided by CXCR5/CXCL13 and
CXCR4/CXCL12.20
Interestingly, while the role of CCR7 in secondary lymphoid
organogenesis is well defined and the features of SLOs in CCR7−/−
are consistent with its ability to organize the architecture of the
follicle, the CCR7 involvement and function in tertiary lymphoid
structures formation are instead rather more ambiguous. On the one
hand, CCR7−/− mice unexpectedly showed the presence of ELS at
various mucosal sites, for example, salivary glands.56 On the other
hand, in a model of chronic Ag-induced arthritis, deleting CCR7 could
inhibit ELS development.57 Furthermore, CCL21 overexpressed in
nonlymphoid organs (liver, pancreas) can induce the development of
ectopic SLOs-like structures.20,26 In trying to resolve the controversy,
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it is worth bearing in mind that the global phenotype of the CCR7−/−
model is characterised by an impairment of the T lymphocytes
negative selection, the T cells migration and, importantly, the Treg
correct functioning. In this model, lymphocytes can unrestrainedly
penetrate different organs and there, in the absence of prop-
erly functional Treg cells, arrange as ectopic lymphoid follicles in
a CCR7-independent way, as opposed to the CCR7-dependent
manner occurring during the ELS-development secondary to
CCR7-ligands overexpression.20,58
Treg cells, however, not only act as negative regulators of ELS gen-
eration but can also be present inside the ELS where they might play
antithetic roles. In fact, if the presence of intra-ELS Treg in neoplastic
diseases usually associates with the suppression of the host response
against cancer cells,59 vice versa, in a model of atherosclerosis, the
infiltration of anti-inflammatory activatedTreg cells skews the immune
response towards an “anti-atherogenic” phenotype, rendering aortic
TLOs protective.60,61
Overall, even if ELS forming in chronically inflamed tissues
are essentially induced and maintained by the same chemokines
and LTs regulating SLOs’ development, these molecules can be
produced at the site of the disease by additional or alternative
sources, often represented by subsets of tissue-specific cells. In
SLOs, the foremost source of CXCL13 in the GC is the network
of FDCs, which originate from LTo and support the affinity matu-
ration of the B cells.31,62 During inflammation also different T cell
subsets (e.g., memory T cells,63 Tfh,49 T peripheral helper [Tph]
cells64) and activated monocytes/macrophages can become CXCL13
producers.65 Moreover, also activated stromal components such as
epithelial cells and myofibroblast-like cells can release CXCL1366 and
CCL21,67 respectively.
Alongsidewith chemokines, also LTs are critically important for TLO
neogenesis, both in cancer and chronically inflamed tissues.45
Lymphoid chemokines and LTs work in concert with numerous
cytokines to shape the cellular microenvironment during tertiary
lymphoid neogenesis. In that context, in addition to the impor-
tance mentioned above of the Th17-related cytokines (IL-17, IL-
22, IL-23) and the Tfh-produced IL-21, available data suggest that
a number of other “positive regulators” contribute to ELS forma-
tion. For example, IL-36 agonists, members of the IL-1 sub-family of
cytokines together with IL-1𝛼, IL-1𝛽 , IL-18, and IL-33,68 have indeed
recently emerged as novel promoters of ELS generation in inflamed
and neoplastic tissues.69 This effect likely depends on the IL-36-
mediated ability to induce proinflammatory cytokines and chemokines
that in turn recruit B/T lymphocytes69 and differentiate Th1 and
IL-17-producing T cells.68
Recent studies have also identified a number of “negative regu-
lators” of ELS. For example, IL-27 has emerged as a negative reg-
ulator of the Th17-mediated generation of ELS in synovia during
inflammatory arthritis.27
In summary, it is evident that lymphoid chemokines undoubtedly
play a vital role in the lymphoid organogenesis and are essential for the
initiation and maintenance of the ELS. The features and relevance of
tissue-specific factors in ELS development in the context of autoimmu-
nity and cancer will be discussed in the next section.
3 ELN IN DISEASES: THE RELEVANCE
OF TISSUE-SPECIFIC FACTORS
As discussed above, the importance of lymphoid chemokines in the
development of ELS is widely accepted. These structures can be
detected in target organs of several pathologic conditions in which
they play diversified roles. In autoimmune diseases, ELS become
microniches of autoreactive activated B cells and plasma cells and
likely contributors to the disease pathogenesis and chronicity. Con-
versely, in persistent infective diseases, ELS might help to confine the
immune reaction to the infected site. Therefore, ELS can improve the
resolution of the infection. However, by the same token, their pres-
ence may also increase the risk of developing autoimmunity through
molecularmimicry. In cancer instead, ELS appear to be able to enhance
the antineoplastic activity of the immune system. Thus, in the final
section of this review, we will discuss the features of ELS in specific
pathologic contexts.
4 AUTOIMMUNE DISEASES: THE
PARADIGM OF RA
Agrowing bodyof evidence has confirmed that ELS characterize target
organs in numerous autoimmune conditions, including Hashimoto thy-
roiditis, myasthenia gravis, type I diabetes, multiple sclerosis, Sjogren’s
syndrome,70 and RA.9,71 In this setting, ELS are chronically triggered
and possibly contribute to sustaining the pathogenic process8 and the
local production of autoreactive antibodies.72
The introduction ofminimally invasive techniques of synovial tissue
sampling73 has empowered the in-depth analysis of the diseased syn-
ovium. Several data about the incidence of ELS and the mechanisms
regulating their development in RA have become available since then,
representing a valuable paradigm of how ectopic lymphoid structures
form and function in autoimmune diseases. However, not all patients
affected by RA develop ELS at the site of the inflammation. ELS can be
detected in the synovial tissues of around40%of patients, but only 10–
25%of these structures acquire features of fully formed TLO including
the presence of a functional GC.25
The presence of a lymphoid-like-synovitis seems to define a subset
of patients with increased disease activity,74 more prone to early bone
erosions (our unpublished data) and particularly difficult to treat.75,76
The factors driving ELN in RA include the local up-regulation of
the classic B lymphoid chemokines CXCL13 and CXCL12,31,62,67,77,78
the production of the BAFF and the a-proliferation-inducing ligand
(APRIL) by fibroblasts-like-synoviocytes,79 the release of CCL21 by
myofibroblast-like stromal cells67 and of CCL20 by activated synovial
fibroblasts and osteoblasts.80,81
In the highly inflamed microenvironment of the rheumatoid syn-
ovia, activated mesenchymal cells become efficient lymphoid-tissue
organizer cells, able to produce chemokines and cytokines that, in
turn, favor ELS generation.77 To this extent, also the release of
cytokines from infiltrating CCR6+ Th17, attracted by CCL20,81 and
Tfh cells gives a further contribution.27 As in SLOs, CXCL13 is pro-
duced by FDCwithin the GC. However, other CXCL13-producing cells
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F IGURE 1 Ectopic lymphoid structures (ELS) generation in the inflamedsynovial tissueofpatients affectedby rheumatoidarthritis (RA). Unin-
flamed synovium shows scant infiltration of immune cells [A, H&E staining]. [Initiation] In response to chronic inflammatory signals characterizing
RA synovitis, several cell types (e.g., adult LTi, Th17, M1macrophages), attracted by homeostatic cytokines (CXCL13, CCL21), behave as initiators
of the ectopic lymphoid neogenesis. Resident stromal cells such as fibroblasts-like-synoviocytes and myofibroblast-like cells act as LTo, contribute
to lymphoid chemokines production, and guide the cellular arrangement of the follicle-like-structure. [Recruitment] In their initial phase, ELS are
characterized by the development of HEVs, which are of fundamental importance for enhancing T and B cells recruitment to the site of inflam-
mation. [ELS organization] Once ELS are formed within the synovial tissue [B, H&E staining], both Ag-presenting FDCs and B/Tfh cells shuttling
into the GC help maintaining these structures. Different gradients of CXCL13 and CCL19/CCL21 support the segregation of B/T cells. Eventually,
B cells differentiate in situ into plasma cells, which produce disease-specific anti-CCP autoantibodies. CCL, chemokine (C-C motif) ligand; CCR,
chemokine (C-Cmotif) receptor; CCP, cyclic citrullinated protein; CXCL, chemokine (C-X-Cmotif) ligand; CXCR, chemokine (C-X-Cmotif) receptor;
ELS, ectopic lymphoid structures; FDCs, follicular dendritic cells; GC, germinal center; HEVs, high endothelial venules; ICAM1, intercellular adhe-
sionmolecule 1; LT𝛽R, lymphotoxin-𝛽 receptor; LTi, lymphoid tissue inducer; LTo, lymphoid tissue organizer; PNAd, peripheral nodal addressin; RA,
rheumatoid arthritis; RANK, receptor activator of NF-𝜅B; RANKL, RANK ligand; Tfh, T follicular helper; Th, T helper.
have been described in the inflamed synovia, for example, a sub-
set of Ag-experienced Th cells originally detected by Manzo et al.63
More recently, a subset of PD1+ CXCR5+ CD4 T cells named Tph
cells has been characterized to be significantly expanded in the
rheumatoid synovitis, where it may provide a prompting signal to
the development of ELS by producing CXCL13/IL-21 and recruiting
B cells/Tfh.64 In keeping with the importance of Tfh, circulating lev-
els of IL-21 seem to correlate with anti-cyclic citrullinated protein
(CCP) antibodies and the severity of RA.82 Silencing the IL-21 path-
way instead improves the clinical outcome in experimental arthritis
models.83 Genetic analyses of lymphoid-like RA synovial tissue have
confirmed the local up-regulation of lymphoid-associated genes, for
example, IL-7, one of the crucial players of the SLO development,84
the IL-21/IL-21R axis,27 and the full set of homeostatic chemokines
CXCL13/CCL19/CCL21.16,62,72,85 Among them, it has been reported
that levels of circulating CXCL13 positively correlate with the local
expression of CXCL13within the rheumatoid synovial tissue86 and are
significantly higher in patients characterized by a synovial lymphoid
transcriptomic profile.85 Serum CXCL13 has been also proposed as a
biomarkerof response to targetedbiologic treatments. It seems indeed
that patients with baseline high levels of CXCL13 in association with
low concentrations of the myeloid marker soluble ICAM1 are more
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likely to respond to anti-IL-6R agents. Vice versa, a serum profiling
characterizedby lowCXCL13/high ICAM1associateswithhigher rates
of response to the TNF𝛼 blockade.85
This is not surprising as TNF𝛼 itself might contribute to synovial
ELN too. In fact, the ELS reversal observed in the synovial tissue of
some RA patients following the inhibition of TNF𝛼 by specific blocking
agents would indirectly imply that TNF𝛼 is itself a contributor to
ectopic lymphoid synovial neogenesis75
As the availability of the homeostatic chemokines increases within
the synovium, the cellular arrangement of the ELS becomes increas-
ingly more “organised,”25,74 eventually enabling the development of
a functionally active GC, which support the occurrence of activation-
induced cytidine deaminase-dependent class-switching and somatic
hypermutation with the production of high affinity, RA-specific
anti-CCP antibodies.72 The crucial elements and steps of the ELS gen-
eration in RA synovial tissue have been depicted in Fig. 1.
5 CANCER: NEW INSIGHTS
Over the last decade, a huge effort has been made to identify and
potentially manipulate for therapeutic purposes the mechanisms con-
trolling the ELN in cancer.45,87
Similarly to autoimmune diseases, the molecular machinery induc-
ing the intra/peritumor ELN seems to largely overlap with the genera-
tionof SLO, including theup-regulationof thehomeostatic chemokines
CXCL13, CCL19, and CCL21.88
For example, studies in lung carcinoma have confirmed that
CXCL13 is produced by FDCs located in the GC-like zone and
constitutes the chemotactic signal for CXCR5+ Tfh, which can be
detected in the same area of FDCs. CCL21, instead, is predomi-
nantly produced in the lymphatic vessels.45 Overall, a more favorable
outcome has been observed in patients with solid cancers, for exam-
ple, breast cancer,89 colorectal carcinomam,90 melanoma,91 and non-
small cell lung cancer92 characterizedby thepresenceofELSwithin the
neoplastic tissue.69
In particular, it has been described that the infiltration of CXCL13-
producing Tfh cells within the intratumor tertiary lymphoid struc-
tures associates to a better clinical outcome in patients with breast
cancer.43,93 A high CXCL13 signature has also been demonstrated
to be a convincing marker of better prognosis in ovarian and colon
cancer.94 Consistently, an improved antitumor immune response has
been associatedwith the presence of highly organized lymphoid struc-
tures including HEVs in both animal models and patients affected
by colorectal carcinoma.95 In keeping with the negative regulatory
effect of Treg cells on ELS development, it has also been shown
that the ablation of this subset during experimental carcinogenesis
methylcholanthrene-induced correlated with the formation of lym-
phoid aggregates. Remarkably, a better clinical outcome was achieved
when the ELSwere properly organized and includedHEV.96
The crucial importance of HEVs has been confirmed in multiple
studies, in which the presence of this peculiar ELS-associated vascula-
ture structure correlateswith better survival rates and decreased inci-
dence of metastasis.45
Therefore, the possibility of “controlling” the development of intra-
tumor ELS to improve the immune reaction to cancer cells represents
an attractive therapeutic option. With this intention, current studies
have tried to delineate the set of chemokines mainly responsible for
cancer-related ELN, eventually identifying a 12-chemokines signature
able to precisely predict the features of the ELS forming at the site of
a tumor.91 Importantly, the definition of the best candidates able to
induce ELN needs to take into account the considerably immunosup-
pressive environment characterizing neoplastic processes.87 Never-
theless, the clinical success of checkpoint inhibitors in the treatment of
solid tumors has validated the approach ofmodulating natural immune
responses as anticancer therapy.97,98
6 CONCLUDING REMARKS
The critical role of lymphoid chemokines in shaping ectopic neoformed
SLOs-like structures has been widely demonstrated. The significance
and functional outcomeof these structures, however, can be extremely
different. In autoimmunediseases, hereexemplifiedbyRA, ELS seemto
actively contribute to the maintenance of the immune response at the
site of inflammation, hence participating in the local development of
autoimmunity and tissue damage. On the contrary, intratumor tertiary
lymphoid structures driven by homeostatic chemokines appear to be
associated with amore favorable prognosis.
Further studies aiming at outlining the context-specificmechanisms
of the ELNwill help shed light and improve the clinical targeting.
In fact, depending on the pathologic process, the therapeutic
approaches to target ELS may hugely vary. On the one hand, agents
inhibiting lymphoid chemokines, LTs and adhesion molecules might be
exploited to contain the persistent immune response in autoimmune
conditions.Conversely, similarly to the successof checkpoint inhibitors
in solid tumors, enhancing immune responses through the develop-
ment of ELS via inducing lymphoid chemokinesmight represent a novel
therapeutic approach for treating cancers.
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